BTIG Reiterates Buy Rating on Boston Scientific

BTIG analyst Marie Thibault has reiterated a buy rating on Boston Scientific Corporation (NYSE: BSX) with a price target of $65. This reaffirmation came on June 16, 2026, as part of BTIG's continued positive outlook on the medical device company.

Boston Scientific Stock Snapshot

Shares of NYSE:BSX traded near $46.70 recently. Boston Scientific has a market capitalization of approximately $69.5 billion. The company boasts a forward P/E ratio of 12.55 and a beta of 0.559, suggesting lower volatility compared to the market. The stock's 52-week range has seen a low of $45.99 and a high of $109.50. Its 50-day moving average is $55.91, while the 200-day moving average stands at $82.10. The company's financial health is supported by a current ratio of 1.9 and a quick ratio of 0.98, with a debt-to-equity ratio of 42.25.

Recent Earnings

Boston Scientific reported revenues of $20.61 billion, reflecting a revenue growth of 11.6%. The company achieved a net margin of 17.3% and a return on equity of 14.7%. Earnings per share stood at $2.39. Investors are keeping an eye on the next earnings release, scheduled for July 29, 2026.

Other Institutional Activity in Boston Scientific

Several institutional investors have made adjustments to their holdings in Boston Scientific. BlackRock, Inc. trimmed its position by 4.17 million shares, leaving it with 131.8 million shares valued at approximately $8.27 billion. On the other hand, Vanguard Capital Management LLC significantly increased its holdings by 96.4 million shares, now owning about 96.4 million shares worth $6.05 billion. FMR LLC reduced its stake by 23.2 million shares, resulting in a total of 74.2 million shares valued at $4.66 billion. Meanwhile, State Street Corp and JPMorgan Chase & Co increased their positions by 2.14 million and 7.98 million shares, respectively.

Insider Buying and Selling at Boston Scientific Corporation

Recent insider activity at Boston Scientific included several buys. On May 20, 2026, David Habiger purchased 2,250 shares at an average price of $55.92, while Edward Ludwig bought 3,580 shares at $56.68, and Cheryl Pegus acquired 1,770 shares at $56.49. Earlier, on May 19, Habiger added 2,200 shares at $56.95. Ellen Zane also bought 3,800 shares on May 7.

Analysts Set New Price Targets

On June 16, 2026, BTIG reiterated its buy rating on Boston Scientific with a $65 price target. Earlier in the month, Truist Securities maintained a buy rating with a $64 target. Canaccord Genuity also held a buy rating, setting a target of $70. Citigroup and Leerink Partners similarly maintained buy ratings with targets of $70 and $74, respectively. Barclays set a higher target at $89, while Wells Fargo downgraded the stock to hold with a $55 target. The consensus among 30 analysts is a strong buy, with a mean target price of $77.10.

About Boston Scientific Corporation

Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, develops and markets medical devices worldwide. The company operates in the MedSurg and Cardiovascular segments, offering products for gastrointestinal, urological, and neurological conditions, as well as cardiac rhythm management and peripheral interventions. Founded in 1979, Boston Scientific is led by CEO Michael F. Mahoney and employs about 59,000 people.

Bottom Line

BTIG's reiterated buy rating and $65 price target reflect confidence in Boston Scientific's growth prospects. With robust earnings and a strong market position, the company remains a key player in the healthcare sector. Institutional investors' varied adjustments to their holdings highlight differing perspectives on the stock's future performance. As always, it's important to remember that analyst ratings and institutional filings are backward-looking and may not reflect the most current market conditions.